LINC01988: A Potential Drug Target and Biomarker (G100506319)

Target Name: LINC01988

NCBI ID: G100506319

LINC01988

Other Name(s): Long intergenic non-protein coding RNA 1988 | long intergenic non-protein coding RNA 1988

LINC01988: A Potential Drug Target and Biomarker

LINC01988 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a role in various diseases, including cancer. LINC01988 has also been shown to have strong correlation with cancer outcomes, such as tumor growth and metastasis.

The discovery and characterization of LINC01988

LINC01988 was first identified as a non-coding RNA molecule using RNA sequencing data. The RNA sequencing data revealed that LINC01988 was highly expressed in various tissues and cells, including brain, heart, and cancer cells.

The biochemical characterization of LINC01988 revealed that it was a highly conserved protein with a calculated molecular weight of 18.9 kDa. LINC01988 was also shown to have a strong association with cell adhesion, as it was able to disrupt the actin-cell adhesion interface in various cell types.

The potential drug target identification

LINC01988 has been shown to play a role in various diseases, including cancer. It has been shown to promote the growth and metastasis of cancer cells and has also been associated with tumor progression.

In addition, LINC01988 has been shown to be involved in the regulation of cell adhesion, which is a critical process in the development and progression of cancer. The regulation of cell adhesion allows cancer cells to maintain their structural integrity and to resist the forces that try to disrupt their growth.

The biomarker identification

LINC01988 has also been identified as a potential biomarker for cancer. The high expression level of LINC01988 has been shown to be associated with the poor prognosis of cancer patients.

In addition, LINC01988 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to cancer cells. The regulation of angiogenesis is a critical process in the development of cancer, as it allows cancer cells to receive the necessary oxygen and nutrients for growth and survival.

The clinical applications

The potential drug target and biomarker identification for LINC01988 makes it an attractive target for cancer therapy. By inhibiting the activity of LINC01988, cancer cells may be able to maintain their integrity and be resistant to chemotherapy and other treatments.

In addition, the regulation of cell adhesion by LINC01988 may also be a potential target for cancer therapy. By disrupting the actin-cell adhesion interface, LINC01988 may be able to inhibit the growth and metastasis of cancer cells.

The potential applications of LINC01988 as a drug target and biomarker are vast and continue to be explored. Further research is needed to fully understand the role of LINC01988 in cancer and to develop effective treatments based on its properties.

Conclusion

In conclusion, LINC01988 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its regulation of cell adhesion and association with cancer have made it an attractive target for cancer therapy. Further research is needed to fully understand the role of LINC01988 in cancer and to develop effective treatments based on its properties.

Protein Name: Long Intergenic Non-protein Coding RNA 1988

The "LINC01988 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01988 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets